Soligenix names Marco Brughera to board
This article was originally published in Scrip
Executive Summary
Princeton, New Jersey-based Soligenix – a clinical stage biopharmaceutical company developing products to treat inflammatory diseases and biodefense medical countermeasures – has named Marco Maria Brughera to its board of directors. Dr Brughera is currently global head of the rare disease franchise for Sigma-tau, he is also a member of the company's board. Furthermore Dr Brughera is currently a member of the board for Italian biopharmaceutical company Gentium.
You may also be interested in...
Accessing Venture Debt From The EIB
Tips from Gergely Krajcsi, senior investment officer at the European Investment Bank, on how biotechs can access loans for faster growth.
In Vivo's 2024 Rising Leaders At A Glance
Top 30 leaders: see the list of industry influencers highlighted in the fifth edition of In Vivo's Rising Leaders series.
In Vivo’s 2024 Rising Leaders
The fifth annual listing of In Vivo’s Rising Leaders includes entrepreneurs and innovators from across the world who represent the next wave of creativity in health care.